Cardiac contractility modulation as bailout in a patient with phospholamban p.Arg14del related cardiomyopathy intolerant to medication: a case report.

ABSTRACT:

Background

Cardiac contractility modulation (CCM) is a novel device-based therapeutic option in patients with heart failure with reduced ejection fraction who are not eligible for cardiac resynchronization therapy. Cardiac contractility modulation enhances cardiac contractility by delivering high-voltage non-excitatory electrical impulses during the absolute refractory period. Cardiac contractility modulation is known to improve left ventricular ejection fraction (LVEF), quality of life, and exercise capacity in heart failure (HF) patients.

Case summary

We present a case of a 77-years-old woman with a cardiomyopathy associated with a pathogenic PLN variant [p.(Arg14del), Dutch founder mutation]. Due to progressive deterioration of LVEF (25%) despite maximally tolerate

SUBMITTER: Verelst FR 

PROVIDER: S-EPMC11852272 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature